The European Patent Office (EPO) has published a patent application, EP4514791A1, for substituted 6-(pyrimidin-4-yl) quinoline compounds that act as cyclin-dependent kinase (CDK) inhibitors. This publication indicates a new potential therapeutic agent for conditions like cancer, as indicated by the A61P 35/00 classification (treatment of cancer).

While this is a patent publication and not a regulatory rule with direct compliance obligations for most entities, it is significant for pharmaceutical and biotechnology companies involved in drug development. Companies operating in this space should be aware of this patent filing as it may impact their own research and development pipelines or intellectual property strategies. The designated states indicate broad European coverage for this patent application.